Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2001 1
2002 1
2003 2
2004 1
2007 1
2008 2
2009 3
2010 7
2011 8
2012 2
2013 5
2014 3
2015 3
2017 1
2018 3
2019 2
2020 2
2021 2
2022 3
2023 5
2024 5
2025 11
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Eikelboom JW, et al. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844192 Free article. Clinical Trial.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
The Significance of Hematuria in Podocytopathies.
Marchel D, Trachtman H, Larkina M, Helmuth M, Lai Yee JY, Fermin D, Bomback AS, Canetta PA, Gipson DS, Mottl AK, Parekh RS, Saha MK, Sampson MG, Lafayette RA, Mariani LH; Nephrotic Syndrome Study Network (NEPTUNE) and Cure Glomerulonephropathy (CureGN). Marchel D, et al. Clin J Am Soc Nephrol. 2024 Jan 1;19(1):56-66. doi: 10.2215/CJN.0000000000000309. Epub 2023 Sep 21. Clin J Am Soc Nephrol. 2024. PMID: 37733352 Free PMC article.
Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis.
Glenn DA, Carver AW, Helmuth ME, Smith AR, Lafayette RA, Ravipati P, Oliverio AL, Rizk DV, Novak J, Lugani F, Bartosh SM, Mucha K, Kiryluk K, Saha MK, Nast CC, Hou J, Biederman LE, Messias N, Rosenberg AZ, Reich HN, Canetta PA, Nachman PH, Nester C, Bou-Matar R, Wadhwani S, Mariani LH, Khalid M; CureGN IgA Working Group. Glenn DA, et al. Clin J Am Soc Nephrol. 2025 Apr 10;20(7):978-992. doi: 10.2215/CJN.0000000707. Clin J Am Soc Nephrol. 2025. PMID: 40208688
Family History in the Context of CKD.
Zanoni F, Marasa M, Carlassara L, Verbitsky M, Khan A, Wang C, Bundy JD, Canetta PA, Bomback AS, Parsa A, Feldman HI, Gharavi AG, Kiryluk K; CRIC Study Investigators and the CureGN Study. Zanoni F, et al. J Am Soc Nephrol. 2025 Mar 11;36(8):1561-1571. doi: 10.1681/ASN.0000000653. J Am Soc Nephrol. 2025. PMID: 40067412
CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.
Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, Hogan JJ, Kiryluk K, Nachman PH, Nast CC, Rheault MN, Rizk DV, Trachtman H, Wenderfer SE, Bowers C, Hill-Callahan P, Marasa M, Poulton CJ, Revell A, Vento S, Barisoni L, Cattran D, D'Agati V, Jennette JC, Klein JB, Laurin LP, Twombley K, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM; CureGN Consortium. Mariani LH, et al. Am J Kidney Dis. 2019 Feb;73(2):218-229. doi: 10.1053/j.ajkd.2018.07.020. Epub 2018 Nov 9. Am J Kidney Dis. 2019. PMID: 30420158 Free PMC article.
The Association of Fibrate Use with Kidney Outcomes and Mortality.
Takahashi R, Shen J, Tran D, Elali I, Dai T, Shah A, Dukkipati R, Ismail A, Sumida K, Thomas F, Rhee CM, Kovesdy CP, Kalantar-Zadeh K. Takahashi R, et al. Among authors: dukkipati r. Clin J Am Soc Nephrol. 2025 Apr 7;20(6):779-787. doi: 10.2215/CJN.0000000683. Clin J Am Soc Nephrol. 2025. PMID: 40193201
Defining subgroups of pediatric nephrotic patients with urine proteomics.
Cummins TD, Mariani LH, Wilkey DW, Jortani SA, Helmuth M, Rane MJ, Merchant ML, Kamigaki Y, Theesfeld C, McCown PJ, Ju W, Dougherty JA, McRitchie S, Pathmasiri W, Kretzler M, Sumner SJ, Smoyer WE, Klein JB; Cure Glomerulonephropathy (CureGN) Consortium. Cummins TD, et al. Sci Rep. 2025 Jul 11;15(1):25064. doi: 10.1038/s41598-025-05150-6. Sci Rep. 2025. PMID: 40646010 Free PMC article.
Glucocorticoid Exposure and Infection in Children and Adults With Glomerular Disease: Findings From the Cure Glomerulonephropathy Study.
Glenn DA, Andrews C, Liu Q, Zee J, Mansfield S, Smith A, O'Shaughnessy MM, Bomback A, Gibson K, Greenbaum LA, Falk RJ, Hogan SL, Mottl A, Denburg MR; CureGN Consortium. Glenn DA, et al. Am J Kidney Dis. 2025 Apr;85(4):528-531. doi: 10.1053/j.ajkd.2024.10.008. Epub 2024 Dec 18. Am J Kidney Dis. 2025. PMID: 39706245 Free PMC article. No abstract available.
60 results